Le Lézard
Classified in: Health
Subjects: SVY, FDA

SSQ Insurance adds pharmacogenetic testing to its group insurance offering


QUEBEC CITY, Oct. 1, 2019 /CNW Telbec/ - SSQ Insurance now offers coverage of pharmacogenetic tests as a new option in group insurance. These tests help analyze how a person's DNA will react to a prescription drug, making it easier for attending physicians to identify the most appropriate drug for each patient. SSQ Insurance aims to make life easier for its insured customers by helping them access optimal treatment, and for its policyholders by making it possible to better control the cost of drugs. 

"Since the treatment of disease is evolving toward personalized solutions for individual patients, pharamacogenetics is quickly becoming a must. We wanted to develop a product adapted to this reality and make it available to our customers across Canada. SSQ Insurance is the first insurer to expand its health insurance offering by adding a clause for pharmacogenetic tests that is separate from the traditional clause for laboratory analyses. In doing so, we demonstrate our proactivity in bringing technological advances in health to our customers," said Éric Trudel, Senior Vice-President of Strategy and Product Management at SSQ Insurance.

At the policyholder's request and in accordance with a reimbursement maximum they will choose, the new clause may be added to their health insurance coverage. To be eligible, pharmacogenetic testing must be prescribed by a physician and carried out in a duly authorized laboratory in Canada. The results of genetic tests are used to identify the most appropriate drugs for the treatment of such conditions as attention deficit disorder (ADD), psychological illnesses, and chronic diseases like hypertension and chronic pain. The results of genetic tests are never provided to the insurer. In fact, any genetic information is excluded when the physician transfers a medical file to the insurer, thus respecting the confidential nature of this information.

The addition of this new clause in health insurance is being made in parallel to a pilot project in disability insurance launched in June 2018. As part of the project, pharmacogenetic testing is offered to insured persons on disability leave who have been diagnosed with depression. The technological advances and the success of the pilot project have allowed SSQ Insurance to develop the new clause now available in group health insurance.

About SSQ Insurance
Founded in 1944, SSQ Insurance is a mutualist company that puts community at the heart of insurance. With assets under management of $12 billion, SSQ Insurance is one of the largest companies in the industry. Working for a community of over three million customers, SSQ Insurance employs over 2,000 people. Leader in group insurance, the company also sets itself apart through its expertise in individual life and health insurance, general insurance and the investment sector. For more information, please visit ssq.ca.

SOURCE SSQ Insurance


These press releases may also interest you

at 11:05
Aptose Biosciences Inc. released highlights from a corporate event and clinical update today held at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL. The event was hosted by the Aptose management team and...

at 10:25
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen...

at 10:20
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL....

at 10:10
Epizyme, Inc. , a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive, mature data at the 2019 American Society of Hematology (ASH) Annual Meeting from its ongoing Phase 2 trial of tazemetostat, an oral...

at 09:35
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019...

at 09:33
Oncopeptides AB  will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an overall response rate (ORR) of 29% and clinical benefit rate (CBR) of 37% in patients with...



News published on 1 october 2019 at 08:30 and distributed by: